PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32275773-5 2020 Paclitaxel neurotoxicity was exacerbated with concomitant P-gp inhibition by valspodar and verapamil, consistent with increased intracellular accumulation of paclitaxel. valspodar 77-86 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 32706283-8 2021 Currently tested drugs included rhodamine 123 (Rh123), vinblastine, and doxorubicin, and all drugs exhibited P-gp-mediated efflux that was inhibited by PSC833. valspodar 152-158 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 32710919-10 2020 The mechanistic action of PEG 400 at gut level was further investigated on human jejunal tissues following the pre-treatment of the P-gp inhibitor PSC 833 (valspodar) on the transport of cimetidine. valspodar 147-154 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 27926506-5 2017 When scar fibroblasts were pre-treated with PSC833 or probenecid, a P-glycoprotein or MRP1 inhibitor respectively, the resistance to verapamil or etoposide was strongly attenuated. valspodar 44-50 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 27783718-6 2016 PSC833 (a P-gp inhibitor) increased the intracellular BZL concentration in both pre-treated and control cells, confirming P-gp participation in BZL efflux. valspodar 0-6 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 27783718-6 2016 PSC833 (a P-gp inhibitor) increased the intracellular BZL concentration in both pre-treated and control cells, confirming P-gp participation in BZL efflux. valspodar 0-6 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 25597754-4 2015 Results We found that crenolanib is a substrate of ABCB1, as evidenced by approximate five-fold resistance of ABCB1-overexpressing cells to crenolanib, reversal of this resistance by the ABCB1-specific inhibitor PSC-833 and stimulation of ABCB1 ATPase activity by crenolanib. valspodar 212-219 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 22118813-9 2012 PSC-833 (valspodar), a selective ABCB1 inhibitor, blocked this efflux, restored apoptotic PARP cleavage and increased doxorubicin sensitivity in IPH-926 and KB-V-1. valspodar 0-7 ATP binding cassette subfamily B member 1 Homo sapiens 33-38 24700236-2 2014 IGROVCDDP and KB-8-5-11 were both resistant to olaparib and resistance was reversible with the P-gp inhibitors elacridar, zosuquidar, and valspodar. valspodar 138-147 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 22118813-9 2012 PSC-833 (valspodar), a selective ABCB1 inhibitor, blocked this efflux, restored apoptotic PARP cleavage and increased doxorubicin sensitivity in IPH-926 and KB-V-1. valspodar 9-18 ATP binding cassette subfamily B member 1 Homo sapiens 33-38 24309308-6 2011 P-gp-mediated transport was measured by using the P-gp substrate calcein-AM in the presence and absence of the P-gp-inhibitor PSC833. valspodar 126-132 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 19423841-2 2009 We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). valspodar 177-186 ATP binding cassette subfamily B member 1 Homo sapiens 58-61 21318225-5 2011 The cyclosporin derivative PSC833, a potent inhibitor of P-glycoprotein, sensitized DX5 but not GARF cells to the cytotoxic effects of daunorubicin. valspodar 27-33 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 19423841-2 2009 We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). valspodar 177-186 ATP binding cassette subfamily B member 1 Homo sapiens 163-166 19423841-2 2009 We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). valspodar 188-194 ATP binding cassette subfamily B member 1 Homo sapiens 58-61 19423841-2 2009 We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). valspodar 188-194 ATP binding cassette subfamily B member 1 Homo sapiens 163-166 15993035-3 2006 The P-gp function was assessed by means of the rhodamine 6G (R6G) efflux from oocytes with P-gp inhibitors such as verapamil and PSC-833. valspodar 129-136 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 16671962-5 2006 A significant inhibition of polarized, basal to apical drug transport by the P-glycoprotein inhibitor PSC-833 was observed for bisoprolol (0.5 and 5 microm) and carvedilol (0.5 microm). valspodar 102-109 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 19188390-7 2009 The P-glycoprotein inhibitor PSC-833 inhibited MXF transport in both directions, whereas probenecid, a multidrug resistance-related protein inhibitor, appeared to have no effect in the Calu-3 model. valspodar 29-36 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 18396325-3 2008 We quantified effects of PSC833, a specific inhibitor of mammalian P-gp (P-glycoprotein, ABCB1), and MK571, which blocks MRP (Multidrug resistance associated protein, ABCC) type transporters, on calcein-am efflux in gill tissue of Mytilus californianus. valspodar 25-31 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 17947497-6 2008 Pgp inhibitors verapamil, cyclosporine A, or PSC833 increased doxorubicin accumulation in the MDR cells up to 79%, and it reversed drug resistance in these cells. valspodar 45-51 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 16223781-7 2006 Cotreatment with specific P-gp inhibitor PSC833 reversed cytoprotective effects of ATRA/FK228. valspodar 41-47 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 16299163-8 2006 Moreover, basal-to-apical transport of [3H]CsA in the Caco-2 cell monolayer was not affected by DHA but was decreased by valspodar (PSC 833), a P-gp inhibitor. valspodar 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 16299163-8 2006 Moreover, basal-to-apical transport of [3H]CsA in the Caco-2 cell monolayer was not affected by DHA but was decreased by valspodar (PSC 833), a P-gp inhibitor. valspodar 132-139 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 15472518-8 2004 Inhibition of P-glycoprotein-mediated transport across Caco-2 monolayers was determined after addition of the P-glycoprotein inhibitor PSC-833. valspodar 135-142 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 21783614-3 2005 In long-term exposed cells, the resistance to diazinon cytotoxicity was reversed in the presence of PSC-833, a P-glycoprotein (P-gp) inhibitor, but not in the presence of MK 571, a Multidrug Resistance Protein (MRP) inhibitor. valspodar 100-107 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 21783614-3 2005 In long-term exposed cells, the resistance to diazinon cytotoxicity was reversed in the presence of PSC-833, a P-glycoprotein (P-gp) inhibitor, but not in the presence of MK 571, a Multidrug Resistance Protein (MRP) inhibitor. valspodar 100-107 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 15384974-8 2004 The concurrent incubation with the pgp inhibitor PSC833 resulted in an enhanced cell kill in 4/5 ITD pgp-positive samples versus two of nine ITD pgp-negative samples. valspodar 49-55 ATP binding cassette subfamily B member 1 Homo sapiens 35-38 15384974-8 2004 The concurrent incubation with the pgp inhibitor PSC833 resulted in an enhanced cell kill in 4/5 ITD pgp-positive samples versus two of nine ITD pgp-negative samples. valspodar 49-55 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 15384974-8 2004 The concurrent incubation with the pgp inhibitor PSC833 resulted in an enhanced cell kill in 4/5 ITD pgp-positive samples versus two of nine ITD pgp-negative samples. valspodar 49-55 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 15788683-9 2005 PSC-833 enhanced mitoxantrone retention and cytotoxicity in cells overexpressing Pgp, but had no effect in cells overexpressing MRP-1, BCRP, or LRP. valspodar 0-7 ATP binding cassette subfamily B member 1 Homo sapiens 81-84 15358539-4 2004 The K562/ADM membrane vesicles showed an ATP-dependent, osmotically sensitive uptake of somatostatin and substance P, which was inhibited by valspodar, an inhibitor of P-glycoprotein. valspodar 141-150 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 15472518-8 2004 Inhibition of P-glycoprotein-mediated transport across Caco-2 monolayers was determined after addition of the P-glycoprotein inhibitor PSC-833. valspodar 135-142 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 15322734-7 2004 The P-glycoprotein inhibitor PSC-833 (1 microM) inhibited the net basal-to-apical transport of cerivastatin in Caco-2 monolayers by 35% (P<0.01) and the MRP inhibitor MK-571 (10 microM) by 50% (P<0.01). valspodar 29-36 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 15244080-10 2004 The potent P-gp inhibitor, PSC-833, had only a moderate effect at blocking loperamide efflux under pH gradient conditions, yet could equilibrate bidirectional transport at pH 7.4. valspodar 27-34 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 12152989-2 2002 There are several potential agents for modulating Pgp-mediated multi-drug resistance, such as cyclosporin A and PSC833, which are currently being evaluated in clinical trials. valspodar 112-118 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 14641819-6 2003 The P-gp inhibitor PSC 833 (valspodar) at 2 microM completely restored sensitivity to IDA. valspodar 19-26 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 12822513-0 2003 Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. valspodar 95-101 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 11284449-6 2001 Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein. valspodar 130-137 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 11566278-7 2001 The presence of P-gp inhibitors SDZ-PSC-833 and cyclosporin A did not modify the mTHPC-induced cytotoxicity. valspodar 32-43 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 11408492-2 2001 Valspodar, a nonimmunosuppressive cyclosporine D analogue that reverses P-glycoprotein-mediated multidrug resistance, in combination with paclitaxel might be active in paclitaxel-resistant and refractory ovarian cancer. valspodar 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 11676863-1 2001 P-Glycoprotein, which mediates multidrug resistance (MDR) in cancer chemotherapy, is a principal target of cyclosporin A and [3"-keto-Bmt(1)]-[Val(2)]-cyclosporin (valspodar; PSC 833). valspodar 164-173 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11284449-6 2001 Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein. valspodar 130-137 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 11284449-6 2001 Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein. valspodar 139-148 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 11284449-6 2001 Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein. valspodar 139-148 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 11123865-5 2001 The most extensively studied modulators, buthionine sulfoximine and valspodar, are involved in reversing resistance caused by glutathione and P-glycoprotein, respectively. valspodar 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 10997946-4 2000 The greatest inhibitory effect on the transcellular transport of digoxin in LLC-MDR1 cells was observed in the presence of valspodar (<0.1 microM), followed by verapamil. valspodar 123-132 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 10636889-3 2000 Reduction of apoptosis correlated with a time-dependent up-regulation of the drug efflux pump multidrug resistance P-glycoprotein (mdr1) in cadmium-treated cells ( approximately 4-fold after 72 h), as determined by immunoblotting with the monoclonal antibody C219 and measurement of intracellular accumulation of the fluorescent probe calcein +/- the mdr1 inhibitor PSC833 (0.5 microM). valspodar 366-372 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 10955805-3 2000 In the present study, the functional activity of P-gp and MRP was determined in 104 de novo AML patients with a flow cytometric assay using rhodamine 123 (Rh123) in combination with PSC833 and carboxyfluorescein (CF) in combination with MK-571. valspodar 182-188 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 10837354-2 2000 Aldosterone secretion is significantly decreased by the PGP inhibitors verapamil, cyclosporin A (CSA), PSC-833, and vinblastine. valspodar 103-110 ATP binding cassette subfamily B member 1 Homo sapiens 56-59 10784624-0 2000 P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. valspodar 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10784624-0 2000 P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. valspodar 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 10784624-10 2000 For the seven patients with Pgp-positive leukemia, the mean ratio increased by 52%, from 545 on day 1 to 830 on day 2 (P<.05) when valspodar was given. valspodar 134-143 ATP binding cassette subfamily B member 1 Homo sapiens 28-31 10832593-6 2000 To address this issue, we examined the ability of the P-glycoprotein inhibitor valspodar to restore paclitaxel accumulation, paclitaxel cytotoxicity, and paclitaxel-induced apoptosis. valspodar 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 10636889-4 2000 When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p < or = 0.001). valspodar 22-28 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 10636889-4 2000 When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p < or = 0.001). valspodar 22-28 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 10636889-4 2000 When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p < or = 0.001). valspodar 22-28 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 10368654-5 1999 Clinically optimal plasma levels of verapamil, cremophor, and PSC833 have been shown to completely block the function of Pgp in Pgp-over expressing cells. valspodar 62-68 ATP binding cassette subfamily B member 1 Homo sapiens 121-124 10368654-5 1999 Clinically optimal plasma levels of verapamil, cremophor, and PSC833 have been shown to completely block the function of Pgp in Pgp-over expressing cells. valspodar 62-68 ATP binding cassette subfamily B member 1 Homo sapiens 128-131 9038218-10 1997 These data suggest that Phe335 is an important binding site on P-glycoprotein for substrates such as dactinomycin and vinblastine and for inhibitors such as cyclosporine and PSC 833. valspodar 174-181 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 9530286-3 1998 In vitro studies in isolated membrane preparations from insect cells infected with MDR1-expressing recombinant baculovirus showed that these inhibitors significantly stimulated P-gp-specific ATPase activity and that this stimulation was inhibited by SDZ PSC 833, a potent inhibitor of P-gp. valspodar 250-261 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 9205006-4 1997 We have focused our efforts of P-gp detection on flow cytometry using a dual technique of P-gp staining with antibodies for the extracellular epitope (MRK16) and a functional analysis of P-gp using the rhodamine efflux assay and the effect of P-gp inhibitors such as SDZ PSC 833. valspodar 267-278 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). valspodar 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). valspodar 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). valspodar 39-45 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). valspodar 39-45 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 9914792-3 1998 Both PSC833 and Cs-A inhibited P-gp-mediated transport of doxorubicin and vinblastine in a concentration-dependent manner and increased the intracellular accumulation of doxorubicin and vinblastine in LLC-GA5-COL150 cells. valspodar 5-11 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 9914792-7 1998 These results indicated that the inhibitory effect of PSC833 on P-gp-mediated transport was 5- to 10-fold more potent than that of Cs-A, and this higher inhibitory effect of PSC833 may be related to the absence of PSC833 transport by P-gp and to the higher lipophilicity of PSC833. valspodar 54-60 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 9914792-7 1998 These results indicated that the inhibitory effect of PSC833 on P-gp-mediated transport was 5- to 10-fold more potent than that of Cs-A, and this higher inhibitory effect of PSC833 may be related to the absence of PSC833 transport by P-gp and to the higher lipophilicity of PSC833. valspodar 54-60 ATP binding cassette subfamily B member 1 Homo sapiens 234-238 8616825-7 1996 Moreover we could correlate MDR1 gene expression and modulation of rhodamine 123 efflux from the leukaemic blasts by proven P-gp MDR chemosensitizing agents such as SDZ PSC 833, dexverapamil and dexniguldipine. valspodar 165-176 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 7559918-8 1995 Both CsA and PSC maximally inhibited P-gp efflux at 3 microM, but only minimally inhibited cell-mediated cytolysis. valspodar 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 34066059-11 2021 PSC833, an ABCB1 inhibitor, and SB203580 rescued the sensitivity to anticancer drugs. valspodar 0-6 ATP binding cassette subfamily B member 1 Homo sapiens 11-16